Document is current

Any future updates will be listed below

Comparison of the Results of Using β-Interferon-1a Formulations 30 μg for Intramuscular Administration and β-Interferon-1a 44 μg for Subcutaneous Injections in Daily Clinical Practice for the Treatment of Multiple Sclerosis

Crossref DOI link: https://doi.org/10.1007/s11055-017-0435-x

Published Online: 2017-05-17

Published Print: 2017-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark